PATENT CLAIM ANALYSIS

Application Number: 15927255
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["530", "388100"]

Abstract:
The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.

Claim (Index 1):
A monoclonal anti-CD95L antibody characterized in that the antibody specifically binds to an epitope of human CD95L comprising the amino acid sequence RNSKYP, preferably RNSKYPQ or RNSKYPQD, and inhibits CD95L induced signalling.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 90.0
- Lexical Diversity: 1.15385
- Patent Class: 530.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15335297', '12742546', '13701151', '10911838', '14163752']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6921367355809166
- 35 USC 102 Novelty (BERT): 0.5362044172043785
- Combined Prediction Score: 0.6765435037432629
- Mean Citation Score: 316.525802
- Max Citation Score: 390.31577
- Similarity Product: 275.50373685484533

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test